The effect of the α2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: Multiple facets of action?

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 6, 2004, Pages 629-638

  Srinivasan, J ^a   Schmidt, Werner J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

2 Antagonists; 5 Hydroxytryptamine; Catalepsy; Dopamine; Idazoxan; Noradrenaline; Open field; Parkinson's disease

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; IDAZOXAN; OXIDOPAMINE; SEROTONIN; 5 HYDROXYINDOLEACETIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEDIAL FOREBRAIN BUNDLE; NERVE DEGENERATION; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSONISM; PREFRONTAL CORTEX; RAT; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; EXPLORATORY BEHAVIOR; METABOLISM; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT; TIME;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CATALEPSY; DISEASE MODELS, ANIMAL; DOPAMINE; EXPLORATORY BEHAVIOR; HYDROXYINDOLEACETIC ACID; IDAZOXAN; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TIME FACTORS;

EID: 3042634487     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0929-2     Document Type: Article

References (101)

1. Al-Shabibi UM, Doggett NS (1978) On the central noradrenergic mechanism involved in haloperidol-induced catalepsy in the rat. J Pharm Pharmacol 30:529-531
2. Anderson RJ (1985) Modification of reserpine induced rigidity by dopaminergic and alpha-adrenergic drugs. Acta Neurol Scand 72:584-589
3. Archer T, Fredriksson A (2000) Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice I: dose-, time- and parameter-dependency. Neurotox Res 1:235-247
4. Asin KE, Wirtshafter D, Fibiger HC (1982) Alterations in drug induced catalepsy and post-decapitation convulsions following brain and spinal cord depletion of norepinephrine by the neurotoxin DSP-4. Life Sci 30:1531-1536
5. Baik JH, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, Le Meur M, Borrelli E (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377:424-428
6. Berridge CW, Dunn AJ (1990) DSP-4-induced depletion of brain norepinephrine produces opposite effects on exploratory behavior 3 and 14 days after treatment. Psychopharmacology (Berl) 100:504-508
7. Bezard E, Brefel C, Tison F, Peyro-Saint-Paul H, Ladure P, Rascol O, Gross CE (1999) Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog Neuropsychopharmacol Biol Psychiatry 23:1237-1246
8. Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate Parkinsonian models. Neurology 57:1829-1834
9. Bing G, Zhang Y, Watanabe Y, McEwen BS, Stone EA (1994) Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 668:261-265
10. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172
11. Bortolozzi A, Artigas F (2003) Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors. Neuropsychopharmacology 28:421-434
12. Brown CM, MacKinnon AC, Redfern WS, Hicks PE, Kilpatrick AT, Small C, Ramcharan M, Clague RU, Clark RD, MacFarlane CB, et al. (1993) The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonist. Br J Pharmacol 108:516-525
13. Calderon SF, Sanberg PR, Norman AB (1988) Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy. Brain Res 450:403-407
14. Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070
15. Cheramy A, Romo R, Godeheu G, Baruch P, Glowinski J (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus - II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience 19:1081-1090
16. Chopin P, Colpaert FC, Marien M (1999) Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 288:798-804
17. Clarke RW, Harris J (2002) RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors. CNS Drug Rev 8:177-192
18. Colpaert FC (1986) Effects of putative α-adrenoceptor antagonists and of other compounds on the loss of the righting reflex and on exophthalmia induced by xylazine in the rat. Drug Dev Res 7:209-220
19. Colpaert FC, Degryse AD, Van Craenendonck HV (1991) Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced Parkinsonian signs. Brain Res Bull 26:627-631
20. Darracq L, Drouin C, Blanc G, Glowinski J, Tassin JP (2001) Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine. Neuroscience 103:395-403
21. Dennis T, L'Heureux R, Carter C, Scatton B (1987) Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 241:642-649
22. Devoto P, Flore G, Pani L, Gessa GL (2001) Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 6:657-664
23. Devoto P, Flore G, Longu G, Pira L, Gessa GL (2003) Evidence for co-release of Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex. Synapse 50:200-205
24. Dickinson SL, Gadie B, Tulloch IF (1988) Alpha 1- and alpha 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. Psychopharmacology (Berl) 96:521-527
25. Domino EF, Ni L, Colpaert F, Marien M (2003) Effects of (±)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys. Receptors Channels 9:335-338
26. Donaldson I, Dolphin A, Jenner P, Mardsen CK, Pycock C (1975) The role of dopamine in rotational behaviour produced by unilateral lesions of the locus coeruleus (abstract). Br J Pharmacol 55:290P
27. Feenstra MG (2000) Dopamine and noradrenaline release in the prefrontal cortex in relation to unconditioned and conditioned stress and reward. Prog Brain Res 126:133-163
28. 2-adrenoceptors. Eur J Pharmacol 442:225-229
29. Fink JS, Smith GP (1980) Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Brain Res 199:359-384
30. Fink K, Schmitz V, Boing C, Gothert M (1995) Stimulation of serotonin release in the rat brain cortex by activation of ionotropic glutamate receptors and its modulation via alpha 2-heteroreceptors. Naunyn Schmiedeberg's Arch Pharmacol 352:394-401
31. Fornai F, Bassi L, Torracca MT, Scalori V, Corsini GU (1995) Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur J Pharmacol 283:99-102
32. Fredriksson A, Archer T (2000) Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice II: interactions with apomorphine. Neurotox Res 1:249-259
33. Garrat JC, Crespi F, Mason R, Marsden CA (1991) Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur J Pharmacol 193:87-93
34. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J (1991) Idazoxan treatment in progressive supranuclear palsy. Neurology 41:986-991
35. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427
36. Grenhoff J, Nisell M, Ferre S, Aston-Jones G, Svensson TH (1993) Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect 93:11-25
37. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111-116
38. Haapalinna A, Leino T, Heinonen E (2003) The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedeberg's Arch Pharmacol 368:342-351
39. Harro J, Merikula A, Lepiku M, Modiri AR, Rinken A, Oreland L (2000) Lesioning of locus coeruleus projections by DSP-4 neurotoxin treatment: effect on amphetamine-induced hyperlocomotion and dopamine D2 receptor binding in rats. Pharmacol Toxicol 86:197-202
40. 2 receptor-G protein interaction in the rat striatum. Brain Res 976:209-216
41. Heffner TG, Hartman JA, Seiden LS (1980) A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav 13:453-456
42. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-DOPA in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14:744-753
43. Hertel P, Fagerquist MV, Svensson TH (1999a) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286:105-107
44. Hertel P, Nomikos GG, Svensson TH (1999b) Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur J Pharmacol 371:153-158
45. Herve D, Blanc G, Glowinski J, Tassin JP (1982) Reduction of dopamine utilization in the prefrontal cortex but not in the nucleus accumbens after selective destruction of noradrenergic fibers innervating the ventral tegmental area in the rat. Brain Res 237:510-516
46. Hicks PB (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47:1609-1615
47. Ihalainen JA, Tanila H (2002) In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse prefrontal cortex. Eur J Neurosci 15:1789-1794
48. Invernizzi RW, Garavaglia C, Samanin R (2003) The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms. Neuropsychopharmacology 28:872-879
49. Jahanshahi M, Jenkins IH, Brown RG, Marsden CD, Passingham RE, Brooks DJ (1995) Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain 118:913-933
50. Jones MD, Hess EJ (2003) Norepinephrine regulates locomotor hyperactivity in the mouse mutant coloboma. Pharmacol Biochem Behav 75:209-216
51. Juhila J, Haapalinna A, Sirvio J, Sallinen J, Honkanen A, Korpi ER, Scheinin M (2003) The alpha2-adrenoceptor antagonist atipamezole reduces the development and expression of D-amphetamine-induced behavioural sensitization. Naunyn Schmiedeberg's Arch Pharmacol 367:274-280
52. Kalkman HO, Neumann V, Tricklebank MD (1997) Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats Naunyn Schmiedeberg's Arch Pharmacol 355:361-364
53. Kalkman HO, Neumann V, Hoyer D, Tricklebank MD (1998) The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550-1556
54. Kamisaki Y, Hamahashi T, Hamada T, Maeda K, Itoh T (1992) Presynaptic inhibition by clonidine of neurotransmitter amino acid release in various brain regions. Eur J Pharmacol 217:57-63
55. Kawahara H, Kawahara Y, Westerink BH (2001) The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis. Eur J Pharmacol 418:177-186
56. Kawai N, Yamamoto T, Baba A, Yamamoto H, Moroji T (1994) Inhibitory effect of idazoxan on forskolin-stimulated adenylate cyclase activity through 5-hydroxytryptaminelA receptors. Arzneimittelforschung 44:1-3
57. Kelland MD, Chiodo AL (1996) Serotonergic modulation of midbrain dopamine systems. In: Ashby CHR Jr (ed) The modulation of dopaminergic neurotransmission. CRC Press, New York, pp 87-122
58. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177-184
59. Kostowski W, Jerlicz M, Bidzinski A, Hauptmann M (1977) Behavioral effects of neuroleptics, apomorphine and amphetamine after bilateral lesion of the locus coeruleus in rats. Pharmacol Biochem Behav 7:289-293
60. Lategan AJ, Marien MR, Colpaert FC (1992) Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study. Life Sci 50:995-999
61. Leviel V, Gobert A, Guibert B (1990) The glutamate-mediated release of dopamine in the rat striatum: further characterization of the dual excitatory-inhibitory function. Neuroscience 39:305-312
62. Llado J, Esteban S, Garcia-Sevilla JA (1996) The alpha 2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1A autoreceptors modulating serotonin synthesis in the rat brain in vivo. Neurosci Lett 218:111-114
63. Majsak MJ, Kaminski T, Gentile AM, Flanagan JR (1998) The reaching movements of patients with Parkinson's disease under self-determined maximal speed and visually cued conditions. Brain 121:755-766
64. Marien M, Lategan A, Colpaert FC (1994) Noradrenergic control of striatal dopamine. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson's disease. CRC Press, Boca Raton, pp 127-138
65. Matsumoto M, Yoshioka M, Togashi H, Mori K, Ueno K, Saito H (1998) Effects of idazoxan on dopamine release in the prefrontal cortex of freely moving rats. Eur J Pharmacol 343:165-170
66. Maura G, Gemignani A, Raiteri M (1982) Noradrenaline inhibits central serotonin release through alpha 2-adrenoceptors located on serotonergic nerve terminals. Naunyn Schmiedeberg's Arch Pharmacol 320:272-274
67. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC (1991) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41:507-523
68. McAllister KH, Rey B (1999) Clozapine reversal of the deficits in coordinated movement induced by D2 receptor blockade does not depend upon antagonism of alpha2 adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 360:603-608
69. Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, Bosc C, Rivet JM, Lacoste JM, Cordi A, Dekeyne A (2000) S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors. II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295:1206-1222
70. Mogenson GJ (1987) Limbic-motor integration. In: Epstein A, Morrison AR (eds) Progress in psychobiology and physiological psychology. Academic Press, New York, pp 117-170
71. Muller CP, Carey RJ, Huston JP (2003) Serotonin as an important mediator of cocaine's behavioral effects. Drugs Today (Barc) 39:497-511
72. Nishi K, Kondo T, Narabayashi H (1991) Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-DOPA. Neurosci Lett 123:244-247
73. Nutt DJ, Lalies M, Hudson A (1993) The effects of alpha-2-adrenoceptor antagonists on extracellular dopamine concentrations in the rat striatum. In: Colpaert F, Briley M (eds) Noradrenergic mechanisms in Parkinson disease. Academic Press, New York, pp 159-172
74. 2 antagonist, in Parkinson's disease. 1st Congress of the Eur Ass Clin Pharmacol Ther, 27-30 September, Paris
75. Prinssen EP, Colpaert FC, Koek W (2002) 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453:217-221
76. Pycock C (1976) Noradrenergic influences on dopamine-dependent behaviour in rats (abstract). Br J Pharmacol 57:424P
77. Pycock C (1977) Noradrenergic involvement in dopamine-dependent stereotyped and cataleptic responses in the rat. Naunyn Schmiedeberg's Arch Pharmacol 298:15-22
78. Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126:572-574
79. Sallinen J, Link RE, Haapalinna A, Viitamaa T, Kulatunga M, Sjoholm B, Macdonald E, Pelto-Huikko M, Leino T, Barsh GS, Kobilka BK, Scheinin M (1997) Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Mol Pharmacol 51:36-46
80. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, Fremeau RT Jr (1994) Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21:133-149
81. Schmidt WJ (1998) Dopamine-glutamate interactions in the basal ganglia. Amino Acids 14:5-10
82. Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621-623
83. Schmidt WJ, Kretschmer BD (1997) Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci Biobehav Rev 21:381-392
84. Soghomonian JJ, Descarries L, Watkins KC (1989) Serotonin innervation in adult rat neostriatum. II. Ultrastructural features: a radioautographic and immunocytochemical study. Brain Res 481:67-86
85. Srinivasan J, Schmidt WJ (2003a) Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci 17:2586-2592
86. Srinivasan J, Schmidt WJ (2003b) Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Behav Brain Res (In press, available online).
87. Srinivasan J, Schmidt WJ (2004) Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic-induced Parkinsonian symptoms in rats. J Neural Transm 111:13-26
88. Svensson TH (1971) On the role of central noradrenaline in the regulation of motor activity and body temperature in the mouse. Naunyn Schmiedeberg's Arch Pharmacol 271:111-120
89. Tassin JP (1992) NE/DA interactions in prefrontal cortex and their possible roles as neuromodulators in schizophrenia. J Neural Transm Suppl 36:135-162
90. Trendelenburg AU, Klebroff W, Hein L, Starke K (2001) A study of presynaptic alpha2-autoreceptors in alpha2A/D-, alpha2B-and alpha2C- adrenoceptor-deficient mice. Naunyn Schmiedeberg's Arch Pharmacol 364:117-130
91. Tucci S, Fernandez R, Baptista T, Murzi E, Hernandez L (1994) Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats. Brain Res Bull 35:125-133
92. Veldhuizen MJ van, Feenstra MG, Heinsbroek RP, Boer GJ (1993) In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br J Pharmacol 109:655-660
93. Veldhuizen MJ van, Feenstra MG, Boer GJ (1994) Regional differences in the in vivo regulation of the extracellular levels of noradrenaline and its metabolites in rat brain. Brain Res 635:238-248
94. Ventura R, Cabib S, Alcaro A, Orsini C, Puglisi-Allegra S (2003) Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. J Neurosci 23:1879-1885
95. Vertes RP, Fortin WJ, Crane AM (1999) Projections of the median raphe nucleus in the rat. J Comp Neurol 407:555-582
96. Villegier AS, Drouin C, Bizot JC, Marien M, Glowinski J, Colpaert F, Tassin JP (2003) Stimulation of postsynaptic alpha1b-and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice. Synapse 50:277-284
97. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-9
98. Yavich L, Sirvio J, Haapalinna A, Riekkinen P Sr (1994) Some unusual effects of alpha 2-adrenergic drugs on cortical high voltage spindles in rats. Eur Neuropsychopharmacol 4:535-538
99. Yavich L, Sirvio J, Haapalinna A, Ylinen A, Mannisto PT (2003) Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol 462:83-89
100. Yoshimoto K, McBride WJ (1992) Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem Res 17:401-407
101. Zhang W, Ordway GA (2003) The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res 112:24-32